Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02712437 · ClinicalTrials.gov registry record · NA
Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast Cancer
A NA study, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02712437 is a NA study that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 4 participants.
The verdict
NCT02712437, a NA study, was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
Women with early stage breast cancer may experience difficulty falling asleep or staying asleep. If this occurs for more than 4 weeks, these participants may have chronic insomnia. Chronic insomnia can lead to difficulty coping with stress, changes in mood, increased use of medications for sleep and an overall decrease in quality of life. The investigators have developed an internet-based website that is designed to help people manage symptoms typically experienced by breast cancer survivors, including insomnia, fatigue, pain and overall poor quality of life. The investigators want to learn whether this type of treatment can reduce chronic insomnia and improve the way subjects feel using both questionnaires and a special form of a wrist watch. This information may help the investigators better manage sleep difficulties in subjects who experience these symptoms after diagnosis of their breast cancer.
Interventions
- BEHAVIORAL PROSPECT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-03-16 |
| Est. Completion | 2017-03-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02712437
The ClinicalTrials.gov registry entry for NCT02712437 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PROSPECT is the first listed.
NCT02712437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02712437 about?
NCT02712437 is a clinical study titled "Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast Cancer". Women with early stage breast cancer may experience difficulty falling asleep or staying asleep. If this occurs for more than 4 weeks, these participants may have chronic insomnia. Chronic insomnia can lead to difficulty coping with stress, changes in mood, increased use of medications for sleep and...
What is the current status of trial NCT02712437?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2016-03-16. Estimated completion is 2017-03-09.
What interventions are being tested in trial NCT02712437?
The interventions under investigation include: PROSPECT (BEHAVIORAL).
Who is sponsoring clinical trial NCT02712437?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.